Fast-track your RNA-based Personalized Cancer Vaccine Development
Your tailored mRNA, delivered with speed and precision
At Exothera, we provide an accelerated RNA manufacturing service tailored for personalized cancer vaccines (PCVs), ensuring rapid, high-quality mRNA production to meet the urgent timelines of individualized therapies. Our optimized process delivers consistent, patient-specific mRNA while maintaining the flexibility required for personalized treatments.
Seamless transition from research to clinical application
With no need for process development or scale-up, our streamlined workflow is designed for patient-by-patient production, ensuring each batch is manufactured with precision and reproducibility. By leveraging in vitro transcription (IVT) optimized for quality, we ensure that every personalized dose meets the highest standards.
How Exothera accelerates your PCV journey:
Rapid turnaround
for mRNA synthesis, customized to your patient’s needs
Consistent, high-quality production
tailored for individualized treatments
A fully optimized, reproducible process,
eliminating unnecessary development steps
GMP readiness from the start,
ensuring a smooth path to clinical manufacturing
Ntensify® : Future-proofing personalized RNA manufacturing
Powered by Quantoom Biosciences’ Ntensify® system, our automated platform ensures that each batch follows the same optimized process, guaranteeing reproducibility and regulatory compliance without the need for process modifications.
Comprehensive mRNA analytical services
- Custom plasmid DNA sourcing or client-provided material
- Co-transcriptional capping for a Cap1 structure, ensuring enhanced stability and translation
- Purified mRNA delivered in nuclease-free water, at optimal concentration (0.5 – 1 mg/mL)
- Analytical testing for concentration, integrity, and identity, with additional services available upon request
